Comparative Pharmacology
Head-to-head clinical analysis: DASETTA 1 35 versus LUPANETA PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DASETTA 1 35 versus LUPANETA PACK.
DASETTA 1/35 vs LUPANETA PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone). Suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus (impenetrability to sperm) and endometrium (reduced likelihood of implantation).
Leuprolide is a synthetic GnRH analog that desensitizes pituitary GnRH receptors, suppressing LH and FSH secretion, leading to decreased sex steroid production (testosterone in males, estrogen in females).
One tablet orally once daily, each containing 1 mg norethindrone acetate and 35 mcg ethinyl estradiol.
Leuprolide acetate 3.75 mg intramuscularly every month or 11.25 mg intramuscularly every 3 months.
None Documented
None Documented
Norethindrone: 5-14 hours (mean 8 hours); ethinyl estradiol: 10-20 hours (mean 14 hours). Clinical context: steady-state achieved within 5-7 days.
Terminal elimination half-life is 6-12 hours (mean 8 hours). Clinical context: supports twice-daily dosing; prolonged in severe renal impairment (CrCl <30 mL/min).
Renal (55-60% as metabolites, 25-30% as unchanged drug and conjugates), biliary/fecal (30-35% as metabolites).
Renal excretion accounts for approximately 50% of the total clearance as unchanged drug, with the remainder undergoing hepatic metabolism followed by biliary/fecal elimination (approx. 30% fecal, 20% biliary).
Category C
Category C
Oral Contraceptive
Oral Contraceptive